Département d'Evaluation et Traitement de la Douleur, Pôle Neurosciences Cliniques, Hôpital Pasteur, 30 avenue de la Voie Romaine, 06002 Nice cedex, France.
Curr Med Res Opin. 2010 Feb;26(2):465-72. doi: 10.1185/03007990903507693.
The PAX study was a naturalistic, prospective survey evaluating treatment expectations and satisfaction in a typical French migraine population.
A total of 1710 patients were recruited by 489 general practitioners across France. Despite a high drop-out rate (due to one or more deviations from protocol and/or missing data), the analysable per-protocol population (PPP) patients (n = 615) remained representative with regard to the overall migraine population. Patients ranked expectations according to four criteria at baseline, and were asked to report satisfaction for each criterion at baseline and for six consecutive attacks. The highest-ranked treatment expectation was rapid relief of headache, followed by pain-free response, relief of associated symptoms, and ability to carry on present activity, respectively.
At inclusion, >50% of patients were using non-specific medications (analgesics, NSAIDs), and 30% reported global satisfaction with treatment. At the end of the survey, >75% of patients were using specific medications (predominantly triptans), and global treatment satisfaction increased to 83%, independent of treatment expectation rankings at baseline.
These survey results suggest that satisfaction with acute migraine treatment increases when specific medications are prescribed, irrespective of which treatment expectation is considered most important at baseline. This emphasizes the need for improvements in the management of migraine, to ensure that optimal treatment is being provided with regard to pharmacological intervention.
PAX 研究是一项自然主义、前瞻性调查,评估了法国典型偏头痛人群的治疗期望和满意度。
共有 1710 名患者由法国各地的 489 名全科医生招募。尽管脱落率很高(由于一项或多项方案偏离和/或数据缺失),但可分析的符合方案人群(PPP)患者(n=615)在总体偏头痛人群中仍具有代表性。患者在基线时根据四个标准对期望进行排名,并要求报告每个标准在基线时和连续 6 次发作时的满意度。排名最高的治疗期望是快速缓解头痛,其次是无痛反应、缓解相关症状和继续当前活动的能力。
在纳入时,超过 50%的患者正在使用非特异性药物(镇痛药、非甾体抗炎药),30%的患者报告对治疗有总体满意度。在调查结束时,超过 75%的患者正在使用特定药物(主要是曲坦类药物),全球治疗满意度增加到 83%,与基线时的治疗期望排名无关。
这些调查结果表明,当开具特定药物时,急性偏头痛治疗的满意度会提高,而不论在基线时认为哪种治疗期望最重要。这强调了需要改进偏头痛的管理,以确保在药物干预方面提供最佳治疗。